Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) serves as a notification of the submission of its Annual Report on Form 20-F for the fiscal year ended December 31, 2011. The filing was made with the Securities and Exchange Commission on March 13, 2012, and this specific Form 6-K was dated March 14, 2012.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It references the inclusion of audited financial statements for the year ended December 31, 2011, within the attached Annual Report on Form 20-F, but does not summarize those figures in this document.
Material Changes
No material changes or comparative financial data versus prior periods are detailed in this specific filing text. The document functions solely as an announcement of the availability of the full annual report.
Guidance, Outlook, and Risks
The filing includes a cautionary statement regarding forward-looking statements under the US Private Securities Litigation Reform Act of 1995. It notes that actual results may differ materially from projections due to risks and uncertainties. Specific factors affecting operations are referenced as being described in the "Risk factors" section of the "Financial review & risk" section within the Annual Report 2011 (Exhibit 15.2).
Investor Verification Checklist
- Verify the availability of the full Annual Report 2011 on Form 20-F at www.gsk.com/corporatereporting or www.sec.gov.
- Review the "Risk factors" section in the Annual Report for detailed operational risks.
- Confirm the date of the Annual General Meeting notice, expected to be available on or about March 26, 2012.
- Check for specific financial metrics (revenue, profit, cash flow) in the audited statements referenced in the Form 20-F, as they are not listed in this summary.